title: European best practice guidelines 14-16: inadequate response to epoetin.
authors.forename: W H
authors.initials: WH
authors.lastname: Hörl
authors.forename: C
authors.initials: C
authors.lastname: Jacobs
authors.forename: I C
authors.initials: IC
authors.lastname: Macdougall
authors.forename: F
authors.initials: F
authors.lastname: Valderrábano
authors.forename: I
authors.initials: I
authors.lastname: Parrondo
authors.forename: K
authors.initials: K
authors.lastname: Thompson
authors.forename: B G
authors.initials: BG
authors.lastname: Carveth
mesh_terms: D000740:Anemia / Q000097:blood* / Q000188:drug therapy*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002097:C-Reactive Protein / Q000032:analysis; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005060:Europe; D006306:Health Surveys; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D000090463:Iron Deficiencies; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy; D010530:Peritoneal Dialysis; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins; D006435:Renal Dialysis
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D002097:C-Reactive Protein